Company news
Foghorn Therapeutics Inc. (NASDAQ:FHTX) news
Every Foghorn Therapeutics Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
August 6, 2026
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 5, 2026
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
May 12, 2026
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
May 7, 2026
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrad...
April 21, 2026
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader...
April 9, 2026
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
March 11, 2026
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
February 23, 2026
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
February 3, 2026
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
January 13, 2026
Foghorn Therapeutics : 2026 January Foghorn Investor Presentation (a105ae)
January 12, 2026
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
January 9, 2026
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
November 25, 2025
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
November 5, 2025
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
November 3, 2025
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
October 30, 2025
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
October 16, 2025
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
August 5, 2025
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
May 22, 2025
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
May 14, 2025
Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announc...
May 6, 2025
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
May 5, 2025
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
May 1, 2025
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader ...
April 28, 2025
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
April 15, 2025
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs...
March 25, 2025
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
March 6, 2025
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
February 25, 2025